Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Advances in Oncology 2019].
Vernadou A, Ferahta N, Mederos N, Ferraro D, Dischl-Antonioni I, Diciolla A, Liapi A, Mosimann V, Latifyan S, Aedo-Lopez V, Berthold D, Digklia A, Michielin O, Montemurro M, Wagner AD, Zaman K, Peters S, Stravodimou A, Sarivalasis A. Vernadou A, et al. Rev Med Suisse. 2020 Jan 15;16(676-7):72-77. Rev Med Suisse. 2020. PMID: 31961089 Review. French.
The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F, Schiappacasse L, Levivier M, Tuleasca C, Cuendet MA, Aedo-Lopez V, Gautron Moura B, Homicsko K, Bettini A, Berthod G, Gérard CL, Wicky A, Bourhis J, Michielin O. Martins F, et al. J Neurooncol. 2020 Jan;146(1):181-193. doi: 10.1007/s11060-019-03363-0. Epub 2019 Dec 14. J Neurooncol. 2020. PMID: 31836957
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Ressler JM, Karasek M, Koch L, Silmbrod R, Mangana J, Latifyan S, Aedo-Lopez V, Kehrer H, Weihsengruber F, Koelblinger P, Posch C, Kofler J, Michielin O, Richtig E, Hafner C, Hoeller C. Ressler JM, et al. J Immunother Cancer. 2021 Feb;9(2):e001701. doi: 10.1136/jitc-2020-001701. J Immunother Cancer. 2021. PMID: 33608376 Free PMC article.
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, Dolcan A, Sarivalasis A, Zurcher JP, Aedo-Lopez V, Dotta-Celio J, Peters S, Guidi M, Wagner AD, Csajka C, Schneider MP. Bandiera C, et al. Among authors: aedo lopez v. Cancers (Basel). 2023 Jan 3;15(1):316. doi: 10.3390/cancers15010316. Cancers (Basel). 2023. PMID: 36612312 Free PMC article.
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors.
da Silva Lopes AM, Colomer-Lahiguera S, Darnac C, Giacomini S, Bugeia S, Gutknecht G, Spurrier-Bernard G, Aedo-Lopez V, Mederos N, Latifyan S, Addedo A, Michielin O, Eicher M. da Silva Lopes AM, et al. Among authors: aedo lopez v. Support Care Cancer. 2023 Jul 22;31(8):484. doi: 10.1007/s00520-023-07934-w. Support Care Cancer. 2023. PMID: 37480546 Free PMC article. Clinical Trial.
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial.
da Silva Lopes AM, Colomer-Lahiguera S, Darnac C, Giacomini S, Bugeia S, Gutknecht G, Spurrier-Bernard G, Cuendet M, Muet F, Aedo-Lopez V, Mederos N, Michielin O, Addeo A, Latifyan S, Eicher M. da Silva Lopes AM, et al. Among authors: aedo lopez v. JMIR Res Protoc. 2023 Oct 18;12:e48386. doi: 10.2196/48386. JMIR Res Protoc. 2023. PMID: 37851498 Free PMC article.
16 results